At Monday’s (6.2.17) closing price of $120.76 per ADS, GW Pharma’s market cap was $3.04 billion, a gain of $170 million since we named the top 10 companies in the marijuana sector last December. The company came public in the United States in 2013 at $8.90 per ADS. Last summer, GW Pharma held a secondary offering of 2.8 million ADSs at $90 a piece.
GW Pharma is developing and preparing to commercialize its orphan epilepsy treatment Epidiolex, which the company has developed on its proprietary cannabinoid product platform.
ADSs traded up about 2.7% Tuesday morning (7.2.17) , at $124.00 in a 52-week range of $118.70 to $120.94. The 12-month consensus price target is $150.78.
For the full article go to 24/7 Wall St.
Read More